FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: February 28, 2011
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Adamchak Mark
2. Date of Event Requiring Statement (Month/Day/Year)
09/18/2024		 3. Issuer Name and Ticker or Trading Symbol
Bionano Genomics, Inc. [BNGO]
(Last)
(First)
(Middle)
C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Principal Accounting Officer
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)

SAN DIEGO, CA 92121		 6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 16,471
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(Month/Day/Year) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (1) 09/30/2028 Common Stock 1,200 $ 77.7 D  
Stock Option (Right to Buy)   (1) 02/28/2029 Common Stock 584 $ 42.5 D  
Stock Option (Right to Buy)   (1) 02/17/2030 Common Stock 753 $ 10.4 D  
Stock Option (Right to Buy)   (2) 03/31/2031 Common Stock 4,999 $ 78.3 D  
Stock Option (Right to Buy)   (2) 02/14/2032 Common Stock 8,750 $ 21.8 D  
Stock Option (Right to Buy)   (2) 02/14/2033 Common Stock 6,899 $ 16.3 D  
Stock Option (Right to Buy)   (2) 06/02/2034 Common Stock 8,750 $ 0.93 D  
Stock Option (Right to Buy)   (3) 06/02/2034 Common Stock 17,500 $ 0.93 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Adamchak Mark
C/O BIONANO GENOMICS, INC.
9540 TOWNE CENTRE DRIVE, SUITE 100
SAN DIEGO, CA 92121		       Principal Accounting Officer  

Signatures

/s/ Jonathan V. Dixon, Attorney-in-Fact 09/30/2024
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The shares subject to the option are fully vested and exercisable.
(2) The shares subject to the option vest monthly over 48 months beginning on the one-month anniversary of the grant date, such that the option shall be fully vested and exercisable on the four-year anniversary of the grant date, subject to continued service through each such applicable vesting date.
(3) 100% of the shares subject to the option vest on the one-year anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.